Call us now :08071793621
Send Inquiry
Send InquiryRascase 1.5 mg Injection
Rascase 1.5 mg Injection Specification
- Pacakaging (Quantity Per Box)
- 1 vial per box
- Salt Composition
- Pegaspargase 1.5 mg
- Origin of Medicine
- Synthetic
- Drug Type
- Injection
- Ingredients
- Pegaspargase
- Physical Form
- Liquid
- Function
- Treats acute lymphoblastic leukemia (ALL)
- Recommended For
- Patients diagnosed with acute lymphoblastic leukemia
- Dosage
- 1.5 mg per administration
- Dosage Guidelines
- To be administered as advised by the healthcare professional
- Suitable For
- Adults and children as recommended by a doctor
- Quantity
- 1 vial
- Storage Instructions
- Store in a refrigerator (2C to 8C). Do not freeze
About Rascase 1.5 mg Injection
Rascase 1.5 mg Injection is a potent medication containing Pegaspargase, suitable for adults and children diagnosed with acute lymphoblastic leukemia (ALL). Each box contains 1 vial of synthetic origin, with a liquid formulation for injection. The recommended dosage is 1.5 mg per administration, to be determined by a healthcare professional. Stored in a refrigerator between 2C to 8C, this drug effectively treats ALL.
FAQs of Rascase 1.5 mg Injection:
Q: What is Rascase 1.5 mg Injection used for?
A: Rascase 1.5 mg Injection is recommended for patients diagnosed with acute lymphoblastic leukemia (ALL).Q: How should Rascase 1.5 mg Injection be stored?
A: It should be stored in a refrigerator between 2C to 8C. Do not freeze the medication.Q: What is the dosage of Rascase 1.5 mg Injection?
A: The dosage for Rascase 1.5 mg Injection is 1.5 mg per administration, as advised by a healthcare professional.Q: Is Rascase 1.5 mg Injection suitable for children?
A: Yes, it is suitable for both adults and children as recommended by a doctor.Q: What is the composition of Rascase 1.5 mg Injection?
A: Rascase 1.5 mg Injection contains Pegaspargase 1.5 mg as its salt composition.
Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
More Products in Critical Care Category
Plasbumin 20% Injection
Physical Form : Liquid
Origin of Medicine : Biologically derived medicine
Suitable For : Adults and elderly patients, Other
Quantity : 100 ml per vial
Recommended For : Patients with low blood albumin levels or requiring plasma restoration
Salt Composition : Human Albumin 20%
Romy 250 mcg Injection
Physical Form : Liquid
Origin of Medicine : To be specified (e.g. synthetic biological origin)
Suitable For : Other, Adults (or as recommended by a healthcare provider)
Quantity : Varies depending on unit (e.g. singleuse vial or prefilled syringe)
Recommended For : Patients as prescribed by a doctor
Salt Composition : Active compound details need clarification for completion
Rasbelon 1.5 mg Injection
Physical Form : Liquid
Origin of Medicine : Allopathic
Suitable For : Other, Adults and pediatric patients (as directed by a medical professional)
Quantity : Single vial
Recommended For : Cancer patients undergoing chemotherapy
Salt Composition : Rasburicase 1.5 mg
Fragmin 2500 IU Injection
Physical Form : Other, Injection
Origin of Medicine : Synthetic
Suitable For : Adults
Quantity : 1 vial
Recommended For : Patients at risk of thrombosis or undergoing surgery
Salt Composition : Dalteparin Sodium (2500 IU)
Send InquiryOur Products
- Alzheimers
- Anti-Cancer
- Anti-Fungal
- Anti-Viral
- Arthritis
- Blood Disorder
- Bone Disease
- Bone Marrow Disorder
- Bowel Disease
- Critical Care
- Gynaecology
- Liver Disease
- Lung Disease
- Macular Degeneration
- Multiple Sclerosis
- Nausea
- Nephrology
- Organ Transplant
- Orthostatic Hypotension
- Osteoporsis
- Psoriasis
- Skin Disorder
- Vaccines
- Pharmaceutical Injection
- Enoxaparin Sodium Medicine
- Oral Suspension
- Pharmaceutical Tablets
- Allopathic Medicine
229, Metro Mall, Bapa Sitaram Chawk, Opp. RAF Camp, S.P. Ring Road, Vastral, Ahmedabad - 382418, Gujarat, India
Dr. Harsh M Patel
(Director)
Mobile :08071793621
Send Inquiry
Send SMS
Developed and Managed by Infocom Network Private Limited.
